Výsledky vyhledávání - "Caroline Streicher"

0559 Solriamfetol Demonstrates Durable Cognitive Improvement in Adults with Obstructive Sleep Apnea and Excessive Daytime Sleepiness

Autor: Hans Van Dongen, Eileen Leary, Christopher Drake, Richard Bogan, Judith Jaeger, Russell Rosenberg, Caroline Streicher, Hannah Kwak, Jay Bates, Herriot Tabuteau

Publikováno v: SLEEP. 46:A246-A246

Introduction Obstructive sleep apnea (OSA) is a common disorder characterized by repeated intermittent airway collapse—often a hypoxic event—resulting in disrupted sleep and excessive daytime sleepiness (EDS). Positive Airway Pressure (PAP) thera

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::118911d6192776bb9a82ff30691d977a
https://doi.org/10.1093/sleep/zsad077.0559

Zobrazit plný text záznamu

Impact of AXS-05 (DEXTROMETHORPHAN-BUPROPION), an Oral NMDA Receptor Antagonist, on Anhedonic Symptoms in Major Depressive Disorder

Autor: Amanda Jones, Roger S. McIntyre, Mark Jacobsen, Caroline Streicher, Zachariah Thomas, Herriot Tabuteau

Publikováno v: CNS Spectrums. 28:264-264

BackgroundTreatments for MDD that can improve both overall depressive and anhedonic symptoms are urgently needed.AXS-05 (dextromethorphan-bupropion) is a novel, oral, investigational NMDA receptor antagonist with multimodal activity being developed f

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1589f6a1e628d8bdf67df01f95e58c89
https://doi.org/10.1017/s1092852923002171

Zobrazit plný text záznamu

AXS-05 (DEXTROMETHORPHAN-BUPROPION) Improves Depressive Symptoms and Functioning in Patients With One Prior Treatment Failure: Results From the Evolve Long-Term, Open Label Study

Autor: Amanda Jones, Caroline Streicher, Shawn Alter, Zachariah Thomas, Herriot Tabuteau

Publikováno v: CNS Spectrums. 28:247-247

BackgroundIn STAR*D, following non-remission with an SSRI, remission rates for second-line treatments were ~ 25%, regardless of the switch strategy employed. Antidepressants with novel mechanisms may improve outcomes in MDD. AXS-05 (dextromethorphan

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::061b19cf48e4b4fa2d1a34885ae8dfa0
https://doi.org/10.1017/s1092852923001840

Zobrazit plný text záznamu

Improvement in Anxiety Symptoms in Depressed Patients Treated With AXS-05 (DEXTROMETHORPHAN-BUPROPION): Results From the Evolve Open-Label, Long-Term Study

Autor: Amanda Jones, Caroline Streicher, Shawn Alter, Zachariah Thomas, Herriot Tabuteau

Publikováno v: CNS Spectrums. 28:260-260

BackgroundInnovative therapies to treat individuals with MDD, especially those with comorbid anxiety, are urgently needed.AXS-05 (dextromethorphan HBr 45 mg-bupropion HCl 105 mg) is a novel, oral, investigational NMDA receptor antagonist with multimo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::463d3582a91821b21508622525b7237b
https://doi.org/10.1017/s1092852923002080

Zobrazit plný text záznamu

Rapid Antidepressant Effects and MADRS Item Improvements With AXS-05 (DEXTROMETHORPHAN-BUPROPION), an Oral NMDA Receptor Antagonist in Major Depressive Disorder: Results From Two Randomized Double-Blind, Controlled Trials

Autor: Amanda Jones, Caroline Streicher, Shawn Alter, Zachariah Thomas, Herriot Tabuteau

Publikováno v: CNS Spectrums. 28:263-263

BackgroundAXS-05 (dextromethorphan-bupropion) is a novel, oral, investigational, NMDA receptor antagonist with multimodal activity being developed for MDD. The dextromethorphan component of AXS-05 is an NMDA receptor antagonist and a sigma-1 receptor

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ba1d84a9313bffdc9bd40377cbdd86fa
https://doi.org/10.1017/s1092852923002158

Zobrazit plný text záznamu

Could Tocilizumab be an Attractive Therapeutic Option for Elderly Patients with Severe COVID-19? A Case Report

Autor: Marion Gaudin, Caroline Streicher, Guillaume Vignaud, Bruno Abraham, Annick Daulange, Xavier Engalenc

Publikováno v: Clinical Drug Investigation

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. https://doi.org/10.1016/S0140-6736(20)30183-5. CAS Article PubMed PubMed Central

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d5a9d3d3744df8b42fd69696133520f

Zobrazit plný text záznamu

Severe rhabdomyolysis induced by possible drug-drug interaction between Ribociclib and Simvastatin

Autor: Caroline Streicher, Nicolas Madranges, Annick Daulange, Laure Vayre

Publikováno v: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 27(3)

Introduction Drug–drug interactions with cyclin-dependent kinases inhibitors 4 and 6 (CDK4/6) are known and should be taken into account. Case report A 68-year-old woman, on prior Simvastatin therapy, developed severe rhabdomyolysis after three wee

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba6567529fd17e354d7b1ff9e38619fa
https://pubmed.ncbi.nlm.nih.gov/32727321

Zobrazit plný text záznamu

Lurasidone in combination with lithium or valproate for the maintenance treatment of bipolar I disorder

Autor: Josephine Cucchiaro, Antony Loebel, Caroline Streicher, Andrei Pikalov, Joseph R. Calabrese, Yongcai Mao

Publikováno v: European Neuropsychopharmacology. 27:865-876

Lurasidone (DS-RAn) has demonstrated efficacy in the acute treatment of bipolar depression, both as monotherapy, and as combination therapy with lithium or valproate. To evaluate the recurrence prevention efficacy of lurasidone for the maintenance tr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c733cb7e2ebdf3c7bd0a370f753b3867
https://doi.org/10.1016/j.euroneuro.2017.06.013

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání